Liraglutid - vozmozhnosti kompleksnogo terapevticheskogo podkhoda v terapii SD 2 tipa
https://doi.org/10.14341/2072-0351-5807
Abstract
References
1. Kreymann, B., Williams, G., Ghatei, M. A. & Bloom, Glucagon-like pep- tide-17–36: a physiological incretin in man. Lancet; 2: 1300–1304, 1987.
2. Deacon, C. F. Therapeutic strategies based on glucagon-like peptide 1. Diabetes; 53: 2181–2189,2004.
3. Drucker, D. J. The biology of incretin hormones. Cell. Metab.; 3: 153– 165, 2006.
4. Drucker, D. J. & Nauck, M. A. The incretin system: glucagon-like peptide-receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 dia- betes. Lancet; 368: 1696–1705, 2006.
5. Deacon, C. F., Johnsen, A. H. & Holst, J. J. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J. Clin. Endocrinol. Metab.; 80: 952–957, 1995.
6. Kieffer, T. J., Mcintosh, C. H. & Pederson, R. A. Degradation of glucose- dependent insulinotropic polypeptide and truncated glucagon-like pep- tide-1 in vitro and in vivo by dipeptidyl peptidase iv. Endocrinology; 136: 3585–3596, 1995.
7. Højberg, P. V. et al. Four weeks of near normalisation of blood glucose im- proves the insulin response to glucagon-like peptide-1 and glucose-de- pendent insulinotropic polypeptide in patients with type 2 diabetes. Diabetologia; 52: 199–207, 2008.
8. Zander, M., Madsbad, S., Madsen, J. L. & Holst, J. J. effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and b-cell function in type 2 diabetes: a parallel-group study. Lancet; 359: 824–830, 2002.
9. Vilsbоll T, Zdravkovic M, Le-Thi T, Krarup T, Schmitz O, Courreges J et al. Liraglutide significantly improves glycemic control, and lowers body weight without risk of either major or minor hypoglycemic episodes in subjects with Type 2 diabetes. Diabetes Care; 30: 1608–1610, 2007.
10. Zinman B et al. Efficacy and safety of the human GLP-1 analog liraglutide in combination with metformin and TZD in patients with type 2 diabetes mellitus (LEAD-4 Met+TZD). Diabetes Care; 32: 1224-1230, 2009.
11. Garber A et al. Liraglutide versus glimepiride monotherapy for type 2 di- abetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet; 373 (9662): 473-481, 2009
12. Marre M et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in sub- jects with type 2 diabetes (LEAD-1 SU). Diabetic Medicine; 268-278, 2009
13. Nauck M et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in type 2 diabetes mellitus (LEAD-2 Met). Diabetes Care; 32:84-90, 2009
14. Russell-Jones D et al. Liraglutide vs insulin glargine and placebo in combina- tion with metformin and sulphonylurea therapy in type 2 diabetes mellitus: a randomised controlled trial (LEAD-5 met+SU). Diabetologia; 52:2046- 2053, 2009.
15. Buse J et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet; 374:39-47, 2009)
16. Garber А, Henry R. et al. Monotherapy with Liraglutide, a Once-daily Human GLP-1 Analog, Provides Sustained Reductions in A1C, FPG, and Weight Compared with Glimepiride in Type 2 Diabetes: LEAD-3 mono 2-year Results 69th ADA Scientific Sessions Abstract Book, Oral presenta- tion 162, 2009
17. Buse J. Sesti G. et al. Switching from Twice-daily Exenatide to Once daily Li- raglutide Improves Glycemic Control in T2D on Oral Agents 69th ADA Sci- entific Sessions Abstract Book, Poster 591, 2009
18. Ghofaili, K. A. et al. Effect of exenatide on b cell function after islet transplan- tation in type 1 diabetes. Transplantation 83, 24–28, 2007.
19. Froud, T. et al. The use of exenatide in islet transplant recipients with chronic allograft dysfunction: safety, efficacy, and metabolic effects. Transplantation; 86: 36–45, 2008.
20. Inzucchi, S. E. & McGuire, D. K. New drugs for the treatment of diabetes: part II: incretin-based therapy and beyond. Circulation; 117: 574–584, 2008.
21. Sokos, G. G. et al. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J. Card. Fail.; 12: 694–699, 2006.
22. Nikolaidis, L. A. et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfu- sion. Circulation; 109: 962–965, 2004.
Review
For citations:
Shestakova M.V. Liraglutid - vozmozhnosti kompleksnogo terapevticheskogo podkhoda v terapii SD 2 tipa. Diabetes mellitus. 2009;12(5):3-6. (In Russ.) https://doi.org/10.14341/2072-0351-5807

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).